Abstract
CPT-11 is a promising new anticancer drug in which 4-piperidinopiperidine is a side-chain structure. In the present studies, we examined the role played by 4-piperidinopiperidine in the pharmacological activity of CPT-11. When T-cell lymphoma RVC cells were incubated with 4-piperidinopiperidine at concentrations higher than 50 μg/ml, the cells underwent apoptosis with a nucleosomal ladder of chromosomal DNA on agarose gels in a dose-dependent manner. We then established a cell line resistant to 4-piperidinopiperidine (4-pp-R), which was about 20-fold more resistant to 4-piperidinopiperidine than the parent RVC cells. Moreover, 4-pp-R cells showed coresistance to CPT-11. However, the growth rate and cell cycle population of 4-pp-R cells were not different from those of the parent RVC cells, and there were no differences between the two cell lines with regard to their drug transport system, CPT-11-metabolizing activity, their activity and amount of topoisomerase I, or their sensitivity to either SN-38 or etoposide, suggesting that the cytotoxicity of CPT-11 is not a consequence of the activity of its metabolite SN-38. The present studies suggested that resistance to CPT-11 is in part due to insensitivity to 4-piperidinopiperidine and its metabolites, since 4-piperidinopiperidine was cytotoxic and 4-pp-R cells were less sensitive to CPT-11.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 7 March 1996 / Accepted: 14 August 1996
Rights and permissions
About this article
Cite this article
Onishi, Y., Oguro, M. & Kizaki, H. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11. Cancer Chemother Pharmacol 39, 473–478 (1997). https://doi.org/10.1007/s002800050601
Issue Date:
DOI: https://doi.org/10.1007/s002800050601